USPTO serial 79413997
AVANTI RESEARCH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 19, 2025
- Examiner
- DELGIZZI, RONALD ERNEST
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AVANTI RESEARCH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Patrick J. Jennings
Patrick J. Jennings Pillsbury Winthrop Shaw Pittman, LLP1200 Seventeenth Street, NWWashington, DC 20036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical compounds in the nature of lipids and lipid mixtures for scientific or research use other than for medical use; lipid compounds for scientific or research use other than for medical use; adjuvants, polymers and excipients, namely, surfactants, dispersants, diluents, disintegrants, emulsifiers, binders, stabilisers and fillers, for scientific or research use other than for medical use; transfection reagents for scientific or research use other than for medical use; chemical reagents for the delivery of lipids for scientific or research use other than for medical use; standard solutions in the nature of lipids and lipid mixtures for use with analytical techniques, namely, mass spectrometry other than for medical use; lipids, synthetic lipids, polymer modified lipids, lipids with modified head groups, lipids with modified acyl chains, bioactive lipids, fluorescent lipids, isotope labelled lipids, oxidized lipids, lipid extracts from natural sources, biological compounds conjugated with modified gold particles for all being for scientific or research use other than for medical use; fatty acids, glycerolipids, glycerophospholipids, sphingolipids, glycosphingolipids, saccharolipids, sterol lipids, prenol lipids, lipid preparations suitable for protein crystallization, lipid preparations suitable for protein solubilization, detergents, amphiphilic detergents, and antibodies, all being for scientific or research use other than for medical use; amino acids, peptides, nucleosides, nucleotides and sugars, and lipid conjugated versions of the aforesaid, all being for scientific or research use other than for medical use; diagnostic and analytical reagents for scientific or research use other than for medical use; formulations in the nature of liposomes, pre-mixed lipid blends and lipids for bicelle formation comprising lipids for scientific or research use other than for medical use; enzymes for scientific or research use; fluorophores and fluorescent probes for scientific or research use other than for medical use; chemical auxiliary agents as raw materials for manufacturing pharmaceutical preparations, nutrient preparations, and food supplements | ACTIVE | — |
| 005 | Lipids, synthetic lipids, polymer modified lipids, lipids with modified head groups, lipids with modified acyl chains, bioactive lipids, fluorescent lipids, isotope labelled lipids, oxidized lipids, lipid extracts from natural sources, biological compounds conjugated with modified gold particles, fatty acids, glycerolipids, glycerophospholipids, sphingolipids, glycosphingolipids, saccharolipids, sterol lipids, prenol lipids, lipid preparations suitable for protein crystallization, lipid preparations suitable for protein solubilization, detergents, amphiphilic detergents, and antibodies, active agents, additives, and excipients in pharmaceutical preparations; adjuvants, polymers and excipients, namely, surfactants, dispersants, diluents, disintegrants, emulsifiers, binders, stabilisers and fillers, all of the aforesaid being for pharmaceutical or medical use; immunostimulatory compounds for pharmaceutical or medical use; isotopes for medical use; transfection reagents for pharmaceutical or medical use; amino acids, peptides, nucleosides, nucleotides and sugars, and lipid conjugated versions of the aforesaid, all being for pharmaceutical or medical use; drug delivery auxiliary agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals | ACTIVE | — |
| 009 | Apparatus and instruments for scientific research in laboratories, namely, extruders, membranes and parts therefor | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Croda International Plc
- Other trademarks owned by Croda International Plc
- Other trademarks owned by Croda International Plc
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named AVANTI RESEARCH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 18, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 1, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 31, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 5, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 5, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 20, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 19, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 19, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 1, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 1, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 25, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 29, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 29, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 10, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 10, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 22, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 13, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 10, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |